LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

AZN

187.14

-0.06%↓

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Închisă

SectorSănătate

7.25 2.98

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

7.04

Maxim

7.29

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.75 49.701
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-29.38% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-23M 360M
Deschiderea anterioară	4.27
Închiderea anterioară	7.25

Sentimentul știrilor

By Acuity

50%

154 / 344 Clasament în Healthcare

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 mai 2026, 16:52 UTC

Evenimente importante

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mai 2026, 23:57 UTC

Câștiguri

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mai 2026, 23:57 UTC

Câștiguri

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mai 2026, 21:54 UTC

Câștiguri

Webco Industries 3Q EPS $11.61 >WEBC

26 mai 2026, 21:54 UTC

Câștiguri

Webco Industries 3Q Sales $179.6M >WEBC

26 mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 mai 2026, 20:58 UTC

Achiziții, Fuziuni, Preluări

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Auto & Transport Roundup: Market Talk

26 mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-29.38% jos

Prognoză pe 12 luni

Medie 5 USD -29.38%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

154 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.